Citation: | GUO Qiuyun, YU Shiying. Comparison of Lorazepam,Diphenhydramine,Haloperidol Combined with Tropisetron and Dexamethasone Combined with Tropisetron Efficacy in Preventing Emesis Induced by Highly Emetogenic Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 798-800. DOI: 10.3971/j.issn.1000-8578.2013.08.017 |
[1] |
Decker GM, DeMeyer ES, Kisko DL.Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy[J].J Support Oncol,2006 ,4(1):35-41, 52.
|
[2] |
Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach[J]. Support Care Cancer, 2002,10(7):519-22.
|
[3] |
Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control[J]. Oncologist,2003,8(2):187-98.
|
[4] |
Jordan K, Kasper C,Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment[J]. Eur J Cancer,2005,41(2):199-205.
|
[5] |
Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)[J].Ann Oncol,2012,23(8):1986-92.
|
[6] |
Fernández-Ortega P, Caloto MT, Chirveches E, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life[J]. Support Care Cancer,2012,20(12):3141-8.
|
[7] |
Hargreaves R, Ferreira JC, Hughes D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting[J]. Ann N Y Acad Sci,2011,1222:40-8.
|
[8] |
Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy[J].Br J Cancer,2006,94(7):1011-5.
|
[9] |
Prommer E.Role of haloperidol in palliative medicine: an update[J].Am J Hosp Palliat Care, 2012,29(4):295-301.
|
[10] |
Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam[J].Clin Pharmacokinet,1981,6(2):89-105.
|
[11] |
Friedlander ML, Kearsley JH, Sims K, et al.Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy[J]. Aust N Z J Med, 1983,13(1):53-6.
|
[12] |
Davies A, Adena MA, Keks NA, et al. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety [J].Clin Ther,1998,20(1):58-71.
|
[13] |
Weschules DJ. Tolerability of the compound ABHR in hospice patients[J]. J Palliat Med, 2008,8(6):1135-43.
|
[14] |
Moon RB. ABHR gel in the treatment of nausea and vomiting in the hospice patient[J]. Int J Pharm Compounding,2006,10:95-9.
|
[15] |
Bleicher J, Bhaskara A, Huyck T, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy- induced nausea/vomiting: results of two pilot trials[J].J Support Oncol,2008,6(1):27-32.
|
[1] | KONG Yan, DONG Qian, LI Shuguang, XU Jinrui, ZHAO Xiaohan, DENG Wenzhao, SHEN Wenbin. Influence of Local Tumor Factors and Radiotherapy Dose on Prognosis of Clinical Stage T1-4N0M0 Esophageal Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 225-232. DOI: 10.3971/j.issn.1000-8578.2025.24.0721 |
[2] | XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 675-681. DOI: 10.3971/j.issn.1000-8578.2022.21.1460 |
[3] | LI Haiyan, ZHOU Xuan, CHEN Yunqing, JI Huihui, SHI Weiping, WANG Chengqin, XIANG Fenggang. Expression of KIF3A in Different Gastric Mucosal Lesions, Metastatic Lymph Nodes and Its Relationship with Metastasis and Prognosis of Gastric Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2018, 45(12): 985-990. DOI: 10.3971/j.issn.1000-8578.2018.18.0627 |
[4] | ZHAO Ruihua, JIANG Wenjing, ZHANG Weijie, CAO Xinguang. Metastasis?associated Lung Adenocarcinoma Transcript1(MALAT1) Expression in Middle Thoracic Esophageal Squamous Cell Cancer Tissues and Its Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2015, 42(12): 1227-1230. DOI: 10.3971/j.issn.1000-8578.2015.12.012 |
[5] | LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007 |
[6] | Zhen Chanjun, Zhou Zhiguo, Song Yuzhi, Qiao Xueying. Analysis of Therapeutic Effect and Prognosis of Radiotherapy for Patients with Esophageal Carcinoma with Supraclavicular Lymph Node Metastasis[J]. Cancer Research on Prevention and Treatment, 2013, 40(01): 90-94. DOI: 10.3971/j.issn.1000-8578.2013.01.023 |
[7] | LI Na, LI Shan-shan, ZHANG Hong-yan, XUAN Xiao-yan, ZHENG Xian-zhao, WANG Feng, YAN Ai-hua. Effects of KISS-1 Transfection on Tumor Growth of Nude Mice[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 136-140. DOI: 10.3971/j.issn.1000-8578.2010.02.004 |
[8] | LI Na, LI Shan-shan, ZHANG Hong-yan, XUAN Xiao-yan, ZHENG Xian-zhao, WANG Feng, YAN Ai-hua. Construction of Eukaryotic Expression Plasmid pcDNA3.1-KISS-1 and Its Metastasis Inhibiting Effect to EC1 Cells[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 265-269. DOI: 10.3971/j.issn.1000-8578.2009.04.002 |
[9] | GAO Zhao-hua. Analysis of Clinicopathologic Characteristics and Prognosis of Colorectal Cancer without Lymph Node Metastasis[J]. Cancer Research on Prevention and Treatment, 2008, 35(04): 272-274. DOI: 10.3971/j.issn.1000-8578.2697 |
[10] | Huang jinqiu, . The significance of tumor angiogenesis in the invasion metastasis and judging the prognosis of gastric carcinoma[J]. Cancer Research on Prevention and Treatment, 1998, 25(6): 441-444. |